

# Roberto Ronca

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1906696/publications.pdf>

Version: 2024-02-01

102  
papers

4,385  
citations

147801

31  
h-index

118850

62  
g-index

104  
all docs

104  
docs citations

104  
times ranked

6560  
citing authors

#	ARTICLE	IF	CITATIONS
1	The lymphatic vasculature: An active and dynamic player in cancer progression. <i>Medicinal Research Reviews</i> , 2022, 42, 576-614.	10.5	18
2	FGFR blockade by pemigatinib treats naïve and castration resistant prostate cancer. <i>Cancer Letters</i> , 2022, 526, 217-224.	7.2	8
3	Fibroblast-derived prolargin is a tumor suppressor in hepatocellular carcinoma. <i>Oncogene</i> , 2022, 41, 1410-1420.	5.9	16
4	Antiproliferative effects of sulphonamide carbonic anhydrase inhibitors C18, SLC-0111 and acetazolamide on bladder, glioblastoma and pancreatic cancer cell lines. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 280-286.	5.2	26
5	Exploring the FGF/FGFR System in Ocular Tumors: New Insights and Perspectives. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3835.	4.1	7
6	Synthesis of 2H-Imidazo[2- $\epsilon$ ,1':2,3] [1,3]thiazolo[4,5-e]isoindol-8-yl-phenylureas with promising therapeutic features for the treatment of acute myeloid leukemia (AML) with FLT3/ITD mutations. <i>European Journal of Medicinal Chemistry</i> , 2022, 235, 114292.	5.5	18
7	Benzenesulfonamides with different rigidity-conferring linkers as carbonic anhydrase inhibitors: an insight into the antiproliferative effect on glioblastoma, pancreatic, and breast cancer cells. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 1857-1869.	5.2	14
8	The FGF/FGFR system in the physiopathology of the prostate gland. <i>Physiological Reviews</i> , 2021, 101, 569-610.	28.8	37
9	Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88. <i>Blood</i> , 2021, 137, 2495-2508.	1.4	4
10	Metastatic colorectal cancer cells maintain the TGF $\beta$ 2 program and use TGFBI to fuel angiogenesis. <i>Theranostics</i> , 2021, 11, 1626-1640.	10.0	45
11	Endogenous Long Pentraxin 3 Exerts a Protective Role in a Murine Model of Pulmonary Fibrosis. <i>Frontiers in Immunology</i> , 2021, 12, 617671.	4.8	11
12	A facile synthesis of diaryl pyrroles led to the discovery of potent colchicine site antimitotic agents. <i>European Journal of Medicinal Chemistry</i> , 2021, 214, 113229.	5.5	13
13	Pentraxin 3 Inhibits the Angiogenic Potential of Multiple Myeloma Cells. <i>Cancers</i> , 2021, 13, 2255.	3.7	6
14	H-ferritin suppression and pronounced mitochondrial respiration make Hepatocellular Carcinoma cells sensitive to RSL3-induced ferroptosis. <i>Free Radical Biology and Medicine</i> , 2021, 169, 294-303.	2.9	34
15	Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity. <i>Blood</i> , 2021, 138, 1705-1720.	1.4	10
16	Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma. <i>European Journal of Medicinal Chemistry</i> , 2021, 221, 113529.	5.5	3
17	Glyco-Coated CdSe/ZnS Quantum Dots as Nanoprobes for Carbonic Anhydrase IX Imaging in Cancer Cells. <i>ACS Applied Nano Materials</i> , 2021, 4, 14153-14160.	5.0	11
18	An Orthotopic Model of Uveal Melanoma in Zebrafish Embryo: A Novel Platform for Drug Evaluation. <i>Biomedicines</i> , 2021, 9, 1873.	3.2	5

#	ARTICLE	IF	CITATIONS
19	Human iPSC modelling of a familial form of atrial fibrillation reveals a gain of function of If and IcaL in patient-derived cardiomyocytes. <i>Cardiovascular Research</i> , 2020, 116, 1147-1160.	3.8	50
20	Enhanced SPARCL1 expression in cancer stem cells improves preclinical modeling of glioblastoma by promoting both tumor infiltration and angiogenesis. <i>Neurobiology of Disease</i> , 2020, 134, 104705.	4.4	23
21	Î²-Galactosylceramidase Promotes Melanoma Growth via Modulation of Ceramide Metabolism. <i>Cancer Research</i> , 2020, 80, 5011-5023.	0.9	12
22	Inhibition of the FGF/FGFR System Induces Apoptosis in Lung Cancer Cells via c-Myc Downregulation and Oxidative Stress. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9376.	4.1	24
23	Design, synthesis, inÂvitro and inÂvivo biological evaluation of 2-amino-3-aryylbenzo[b]furan derivatives as highly potent tubulin polymerization inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2020, 200, 112448.	5.5	25
24	Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer. <i>Cancer Research</i> , 2020, 80, 1564-1577.	0.9	10
25	FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradationâ€“Induced Mitochondrial Oxidative Stress. <i>Cancer Research</i> , 2020, 80, 2340-2354.	0.9	41
26	FGF/FGFR Axis-Blockade Leads to Anti-Tumor Activity in Waldenstrom's Macroglobulinemia By Silencing MYD88. <i>Blood</i> , 2020, 136, 43-44.	1.4	1
27	Design, synthesis and biological evaluation of novel vicinal diaryl-substituted 1H-Pyrazole analogues of combretastatin A-4 as highly potent tubulin polymerization inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2019, 181, 111577.	5.5	22
28	Hyper-Activation of STAT3 Sustains Progression of Non-Papillary Basal-Type Bladder Cancer via FOSL1 Regulome. <i>Cancers</i> , 2019, 11, 1219.	3.7	32
29	Long Pentraxin-3 Follows and Modulates Bladder Cancer Progression. <i>Cancers</i> , 2019, 11, 1277.	3.7	24
30	The Autocrine FGF/FGFR System in both Skin and Uveal Melanoma: FGF Trapping as a Possible Therapeutic Approach. <i>Cancers</i> , 2019, 11, 1305.	3.7	18
31	PTX3 Modulates Neovascularization and Immune Inflammatory Infiltrate in a Murine Model of Fibrosarcoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4599.	4.1	14
32	Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2- <i>c</i> ]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1274-1290.	6.4	33
33	Synthesis, inÂvitro and inÂvivo biological evaluation of substituted 3-(5-imidazo[2,1- <i>b</i> ]thiazolylmethylene)-2-indolinones as new potent anticancer agents. <i>European Journal of Medicinal Chemistry</i> , 2019, 166, 514-530.	5.5	4
34	Evaluating the effects of fluorine on biological properties and metabolic stability of some antitubulin 3-substituted 7-phenyl-pyrroloquinolinones. <i>European Journal of Medicinal Chemistry</i> , 2019, 178, 297-314.	5.5	10
35	Circulating microRNAs and Their Role in Multiple Myeloma. <i>Non-coding RNA</i> , 2019, 5, 37.	2.6	10
36	Caveolin-1 enhances metastasis formation in a human model of embryonal rhabdomyosarcoma through Erk signaling cooperation. <i>Cancer Letters</i> , 2019, 449, 135-144.	7.2	17

#	ARTICLE	IF	CITATIONS
37	Natural Hydrogel-Based Bio-Scaffolds for Sustaining Angiogenesis in Beige Adipose Tissue. <i>Cells</i> , 2019, 8, 1457.	4.1	10
38	Influenza virus entry via the GM3 ganglioside-mediated platelet-derived growth factor receptor $\beta$ signalling pathway. <i>Journal of General Virology</i> , 2019, 100, 583-601.	2.9	34
39	Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple Myeloma. <i>Blood</i> , 2019, 134, 3104-3104.	1.4	2
40	Overcoming the Supportive Stroma-Induced Proliferation in Waldenstrom's Macroglobulinemia By Selective Inhibition of the FGF/FGF-Receptor Axis. <i>Blood</i> , 2019, 134, 1822-1822.	1.4	0
41	Abstract C121: Long Pentraxin-3 modulates bladder cancer progression. , 2019, , .		0
42	Abstract C052: FGF trapping impairs multiple myeloma growth through c-Myc degradation-induced mitochondrial oxidative stress. , 2019, , .		0
43	Paracrine interactions of cancer-associated fibroblasts, macrophages and endothelial cells: tumor allies and foes. <i>Current Opinion in Oncology</i> , 2018, 30, 45-53.	2.4	32
44	Long pentraxin 3: A novel multifaceted player in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1869, 53-63.	7.4	65
45	Long Pentraxin 3-Mediated Fibroblast Growth Factor Trapping Impairs Fibrosarcoma Growth. <i>Frontiers in Oncology</i> , 2018, 8, 472.	2.8	24
46	Improvement and extension of anti-EGFR targeting in breast cancer therapy by integration with the Avidin-Nucleic-Acid-Nano-Assemblies. <i>Nature Communications</i> , 2018, 9, 4070.	12.8	62
47	Long Pentraxin-3 Modulates the Angiogenic Activity of Fibroblast Growth Factor-2. <i>Frontiers in Immunology</i> , 2018, 9, 2327.	4.8	60
48	Choline Kinase Alpha Inhibition by EB-3D Triggers Cellular Senescence, Reduces Tumor Growth and Metastatic Dissemination in Breast Cancer. <i>Cancers</i> , 2018, 10, 391.	3.7	23
49	Future applications of FGF/FGFR inhibitors in cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 861-872.	2.4	76
50	Uptake Profiles of Human Serum Exosomes by Murine and Human Tumor Cells through Combined Use of Colloidal Nanoplasmonics and Flow Cytofluorimetric Analysis. <i>Analytical Chemistry</i> , 2018, 90, 7855-7861.	6.5	25
51	Dendritic cells in inflammatory angiogenesis and lymphangiogenesis. <i>Current Opinion in Immunology</i> , 2018, 53, 180-186.	5.5	37
52	Abstract A039: FGF/PTX3 crosstalk in bladder cancer: novel prognostic and therapeutic implications. , 2018, , .		0
53	Abstract B134: Inhibition of the fibroblast growth factor system by a new FGF trap induces oxidative stress and mitochondrial apoptosis in multiple myeloma cells. , 2018, , .		0
54	Inflammation and N-formyl peptide receptors mediate the angiogenic activity of human vitreous humour in proliferative diabetic retinopathy. <i>Diabetologia</i> , 2017, 60, 719-728.	6.3	33

#	ARTICLE	IF	CITATIONS
55	FGF Ligand Traps for the Therapy of FGF-Dependent Tumors. , 2017, , 237-269.		0
56	Synthesis and Biological Evaluation of 2-Methyl-4,5-Disubstituted Oxazoles as a Novel Class of Highly Potent Antitubulin Agents. Scientific Reports, 2017, 7, 46356.	3.3	17
57	Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach. , 2017, 179, 171-187.		152
58	Contribution of vascular endothelial growth factor receptor-2 sialylation to the process of angiogenesis. Oncogene, 2017, 36, 6531-6541.	5.9	33
59	Tumor angiogenesis revisited: Regulators and clinical implications. Medicinal Research Reviews, 2017, 37, 1231-1274.	10.5	138
60	U94 of human herpesvirus 6 down-modulates Src, promotes a partial mesenchymal-to-epithelial transition and inhibits tumor cell growth, invasion and metastasis. Oncotarget, 2017, 8, 44533-44549.	1.8	11
61	Fibroblast growth factor modulates mast cell recruitment in a murine model of prostate cancer. Oncotarget, 2017, 8, 82583-82592.	1.8	31
62	Monomeric gremlin is a novel vascular endothelial growth factor receptor-2 antagonist. Oncotarget, 2016, 7, 35353-35368.	1.8	34
63	The Novel Antitubulin Agent TR-764 Strongly Reduces Tumor Vasculature and Inhibits HIF-1 $\alpha$ Activation. Scientific Reports, 2016, 6, 27886.	3.3	13
64	Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors. Journal of Medicinal Chemistry, 2016, 59, 4651-4663.	6.4	29
65	Design and Synthesis of Potent in Vitro and in Vivo Anticancer Agents Based on 1-(3,4,5-Trimethoxyphenyl)-2-Aryl-1H-Imidazole. Scientific Reports, 2016, 6, 26602.	3.3	29
66	Vascular disrupting activity of combretastatin analogues. Vascular Pharmacology, 2016, 83, 78-89.	2.1	17
67	Blocking the FGF/FGFR system as a two-compartment antiangiogenic/antitumor approach in cancer therapy. Pharmacological Research, 2016, 107, 172-185.	7.1	69
68	HDAC7 inhibition resets STAT3 tumorigenic activity in human glioblastoma independently of EGFR and PTEN: new opportunities for selected targeted therapies. Oncogene, 2016, 35, 4481-4494.	5.9	30
69	Abstract 1233:In vitro and in vivo pharmacological study of EB-3D: a novel choline kinase inhibitor for breast cancer treatment. , 2016, , .		0
70	The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors. Oncotarget, 2015, 6, 4633-4648.	1.8	10
71	The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. Expert Opinion on Therapeutic Targets, 2015, 19, 1361-1377.	3.4	72
72	Design, Synthesis, in Vitro, and in Vivo Anticancer and Antiangiogenic Activity of Novel 3-Arylamino-benzofuran Derivatives Targeting the Colchicine Site on Tubulin. Journal of Medicinal Chemistry, 2015, 58, 3209-3222.	6.4	47

#	ARTICLE	IF	CITATIONS
73	Cavin-1 and Caveolin-1 are both required to support cell proliferation, migration and anchorage-independent cell growth in rhabdomyosarcoma. <i>Laboratory Investigation</i> , 2015, 95, 585-602.	3.7	37
74	Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy. <i>Cancer Cell</i> , 2015, 28, 225-239.	16.8	111
75	A long pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven steroid hormone-regulated cancers. <i>Oncotarget</i> , 2015, 6, 13790-13802.	1.8	27
76	Antiangiogenic effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, mediated by AMPK activation. <i>FASEB Journal</i> , 2014, 28, 1132-1144.	0.5	38
77	Molecular cloning and knockdown of galactocerebrosidase in zebrafish: New insights into the pathogenesis of Krabbe's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 665-675.	3.8	26
78	Abstract 178: Stromal expression of long Pentraxin-3 impairs tumor growth and metastasis. , 2014, , .		0
79	TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis. <i>Angiogenesis</i> , 2013, 16, 647-662.	7.2	33
80	Matrigel plug assay: evaluation of the angiogenic response by reverse transcription-quantitative PCR. <i>Angiogenesis</i> , 2013, 16, 469-477.	7.2	38
81	Long Pentraxin-3 Inhibits Epithelialâ€“Mesenchymal Transition in Melanoma Cells. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2760-2771.	4.1	68
82	Inhibition of angiogenesis by Î²-galactosylceramidase deficiency in globoid cell leukodystrophy. <i>Brain</i> , 2013, 136, 2859-2875.	7.6	32
83	Long pentraxinâ€“3 as an epithelialâ€“stromal fibroblast growth factorâ€“targeting inhibitor in prostate cancer. <i>Journal of Pathology</i> , 2013, 230, 228-238.	4.5	64
84	Abstract C4: TR-764 is a novel tubulin binding agent with strong antiangiogenic activity.. , 2013, , .		0
85	Phage Displayed Peptides/Antibodies Recognizing Growth Factors and Their Tyrosine Kinase Receptors as Tools for Anti-Cancer Therapeutics. <i>International Journal of Molecular Sciences</i> , 2012, 13, 5254-5277.	4.1	7
86	Long Pentraxin 3/Tumor Necrosis Factor-Stimulated Gene-6 Interaction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 696-703.	2.4	69
87	Embryonic Stem Cells as a Model System to Elucidate Early Events in Cardiac Specification and Determination. , 2011, , .		0
88	Long Pentraxin-3 Inhibits FGF8b-Dependent Angiogenesis and Growth of Steroid Hormoneâ€“Regulated Tumors. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1600-1610.	4.1	53
89	Antiangiogenic Activity of a Neutralizing Human Single-Chain Antibody Fragment against Fibroblast Growth Factor Receptor 1. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 3244-3253.	4.1	28
90	Fibroblast growth factor receptorâ€“1 phosphorylation requirement for cardiomyocyte differentiation in murine embryonic stem cells. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 1489-1498.	3.6	11

#	ARTICLE	IF	CITATIONS
91	Impact of VEGF-dependent tumour microenvironment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice. <i>Journal of Pathology</i> , 2009, 219, 455-462.	4.5	17
92	Delivering cytokines at tumor site: The immunocytokine-conjugated anti-EDB-fibronectin antibody case. <i>Immunobiology</i> , 2009, 214, 800-810.	1.9	26
93	Inflammatory cells and chemokines sustain FGF2-induced angiogenesis. <i>European Cytokine Network</i> , 2009, 20, 39-50.	2.0	114
94	Engineered vascular-targeting antibody-interferon- $\beta$ fusion protein for cancer therapy. <i>International Journal of Cancer</i> , 2005, 116, 304-313.	5.1	101
95	Fibroblast Growth Factor Receptor-1 Expression Is Required for Hematopoietic but not Endothelial Cell Development. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 944-949.	2.4	35
96	Antiangiogenic Activity of Semisynthetic Biotechnological Heparins. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 71-76.	2.4	35
97	Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. <i>Cytokine and Growth Factor Reviews</i> , 2005, 16, 159-178.	7.2	1,126
98	Distinct Role of Fibroblast Growth Factor-2 and Vascular Endothelial Growth Factor on Tumor Growth and Angiogenesis. <i>American Journal of Pathology</i> , 2003, 162, 1913-1926.	3.8	167
99	Fibroblast Growth Factor Receptor-1 Is Essential for In Vitro Cardiomyocyte Development. <i>Circulation Research</i> , 2003, 93, 414-420.	4.5	117
100	Heparin Derivatives as Angiogenesis Inhibitors. <i>Current Pharmaceutical Design</i> , 2003, 9, 553-566.	1.9	102
101	Gene expression profile in fibroblast growth factor 2-transformed endothelial cells. <i>Oncogene</i> , 2002, 21, 2433-2440.	5.9	30
102	Gene expression profile in fibroblast growth factor 2-transformed endothelial cells. , 0, .		1